SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation today announced that sales of its flagship BioMark™ System for Genetic Analysis surpassed 100 cumulative units in the field. The BioMark system, based on proprietary microfluidic chips called integrated fluidic circuits (IFCs), provides high throughput real-time qPCR enabling researchers to streamline their experimental workflow, increase throughput and lower costs.
